Nutritional Value of Original Limu

In light of the myriad of fucoidan's cellular level health benefits, plus the antioxidants and glyconutrients in limu moui, its little wonder that the experiences of drinking Original Limu covers a vast range of health benefits. The following is an abbreviated list of the known benefits of drinking Original limu.

Increased Energy
Restful sleep
                            Strengthens Bone and teeth                          
Improved joint mobility
Enhances the immune function
Healthy cell growth
Healthy gastrointestinal function
Healthy blood glucose levels
Healthy cholesterol levels
Smoother, softer skin
                           Improved overall health and well-being                        

Allergy Relief
Anti-Oxidant Properties
Anti-Aging Problems

The news about Original Limu has spread rapidly by word of mouth, but also caught the attention of national media outlets. The product has appeared in several prominent publications, including the Wall Street Journal, USA Today, Biomed Business Journal, Natural Health and Women's Health and Fitness. Original Limu has also been featured on all four major television news networks: ABC, CBS, NBC and FOX.

Fucoidan is hailed in reputable medical journals like:

Anticancer Research
Infection and Immunity
The British Journal of Pharmacology
Nutrition and Cancer
Developmental Biology
The Journal of Molecular Immunology
Journal of Neuroimmunology
Antibiotics and Chemotherapy
Brazilian Journal of Medical and Biological Research

The Nutrients of LIMU

Limu grows naturally in the ocean. It is not synthesized in a lab, so percentages of each nutrient cannot be quantified. However, each bottle of Original Limu contains 83% of the fucoidan rich Limu Moui extract.
                                           - Your Immune System -                                            
The immune system is the bodys' natural defense against infectious organisms & other invaders. It is a complex network of specialized cells that defend the body against attacks and can also fight cancers. This battle by our immune system is continuous, and without it we would quickly be ravaged by diseases.
A healthy immune system recognizes antigens that threaten your health and, through precise cell-to-cell communication, marshals forces to defend against and attack any invaders. After absorbing the foreign invader, special cells called macrophages secrete growth factors that promote a controlled inflammatory reaction to initiate the wound healing process.
Sometimes our immune system attacks our own cells. When that happens, the result is an autoimmune disease, such as Lupus erythermatosis (SLE) and rheumatoid arthritis. Unfortunately, modern medicine has no cures, and treatments, such as steroids, can damage tissues, bones, and our immune system.

77 Known Nutrients 
Saccharides-Glyconutrients (Essential Sugars)
Alginic Acid
Uronic Acid
                            Amino Acids                           
Aspartic Acid
Glutamic Acid

B1 (Thiamin)
B2 (Riboflavin)
B3 (Niacin)
B5 (Pantothenic Acid)
 Beta carotene


 Independent Clinical Research Findings (776+) continue to shock the Scientific Community. As a Certified Oncology RN for over 20 discoveries by independent researchers, many of them Hematology and Oncology Doctors, have forever changed the way I look at healthcare. Today I share Original Limu with friends, family and strangers because I know the power of this unique liquid nutrition. Sometimes we need to step off the common path to make a real difference in life. Today I'm enjoying both paths. Please take a look at these remarkable scientific findings on Original Limu's key ingredient - Fucoidan

Oversulfation of fucoidan enhances its anti-angiogenic and antitumor activities. Koyanagi S, Tanigawa N, Nakagawa H, Soeda S, Shimeno H.

Department of Biochemistry, Faculty of Pharmaceutical Sciences, Fukuoka University, 8-19-1 Nanakuma, Jonan-ku, Fukuoka 814-0180, Japan.

Fucoidan, a sulfated polysaccharide extracted from brown seaweed, has anticoagulant and antithrombotic activities. Unlike heparin, it shows an inhibitory action on the progression and metastasis of malignant tumors, although the precise mechanisms have not been elucidated. We have demonstrated previously that fucoidan can inhibit tube formation following migration of human umbilical vein endothelial cells (HUVEC) and that its chemical oversulfation enhances the inhibitory potency. In this study, we tested the hypothesis that fucoidan may suppress tumor growth by inhibiting tumor-induced angiogenesis. Both natural and oversulfated fucoidans (NF and OSF) significantly suppressed the mitogenic and chemotactic actions of vascular endothelial growth factor 165 (VEGF(165)) on HUVEC by preventing the binding of VEGF(165) to its cell surface receptor. The suppressive effect of OSF was more potent than that of NF, suggesting an important role for the numbers of sulfate groups in the fucoidan molecule. Consistent with its inhibitory actions on VEGF(165), OSF clearly suppressed the neovascularization induced by Sarcoma 180 cells that had been implanted in mice. The inhibitory action of fucoidan was also observed in the growth of Lewis lung carcinoma and B16 melanoma in mice. These results indicate that the antitumor action of fucoidan is due, at least in part, to its anti-angiogenic potency and that increasing the number of sulfate groups in the fucoidan molecule contributes to the effectiveness of its anti-angiogenic and antitumor activities.

PMID: 12504793 [PubMed - indexed for MEDLINE]

Immunological analysis of inhibition of lung metastases by fucoidan (GIV-A) prepared from brown seaweed Sargassum thunbergii. Itoh H, Noda H, Amano H, Ito H.

Laboratory of Marine Biochemistry, Faculty of Bioresources, Mie University, Tsu, Japan.

The antimetastatic effect of GIV-A (fucoidan) and/or 5-FU was examined in an experimental model of lung metastases induced by Lewis lung carcinoma in mice. Injection of GIV-A i.p. after removal of the implanted primary tumor inhibited the development of lung metastases. Combination treatment with GIV-A and 5-FU inhibited significantly the lung metastases. The number of peritoneal macrophages, total cells and macrophages in the lung increased in mice treated with GIV-A. Binding of the third component of complement (C3) cleavage products (C3b) to the C3 receptor on peritoneal macrophages after i.v. injection of GIV-A was enhanced, as shown by the fluorescent antibody technique. Lung metastases were inhibited by i.v. injection of peritoneal macrophages activated with GIV-A. GIV-A depressed aniline hydroxylase and aminopyrine demethylase activities of the hepatic microsomal drug-metabolizing system in tumor-bearing mice. Moreover, the concentration of 5-FU in the tissues (lung, liver, kidney, spleen and blood) was increased significantly by coadministration of GIV-A. The picryl chloride-induced delayed type hypersensitivity (PC-DTH) response in mice was depressed after the implantation of tumor and treatment with 5-FU. GIV-A restored the suppression of PC-DTH by 5-FU, but did not increase the PC-DTH of normal mice. GIV-A not only enhanced the degree of spleen cell-mediated sheep red blood cell (SRBC) hemolysis (quantitative hemolysis of SRBC), the indexes of the spleen and thymus and the number of spleen cells, but also restored the suppressive effect of 5-FU. In the group receiving GIV-A, the percentages of splenic Thy1.2-, L3T4- and asialo GM1-positive cells were significantly increased as compared with the tumor-bearing mice treated with saline. Furthermore, the L3T4+/Lyt2+ ratio showed a tendency to increase, and the Lyt2+/Thy1.2+ ratio was decreased. These results suggest that the antitumor effect of GIV-A may be correlated with the changing pattern of the Thy1.2-, L3T4- and asialo GM1-positive cells, C3 activation, macrophage activation and depression of the hepatic microsomal drug-metabolizing system. These findings raise the possibility that GIV-A may have clinical value in the prevention of cancer metastasis.

PMID: 8572581 [PubMed - indexed for MEDLINE]

Fucoidan, the key ingredient in Original Limu, has captured the attention of scientists researching cancer. The findings are stunning. Just two of the more recent studies reinforce the possibility that this key ingredient may provide what the immune system needs to promote healthy cells, as well as, use as a potential cancer therapy in the future.

Fucoidan stimulation induces a functional maturation of human monocyte-derived dendritic cells.
Yang M, Ma C, Sun J, Shao Q, Gao W, Zhang Y, Li Z, Xie Q, Dong Z, Qu X.

Institute of Basic Medical Sciences, Qilu Hospital, Shandong University, Jinan, 250012, Shandong, People's Republic of China; Institute of Immunology, School of Medicine, Shandong University, Jinan, 250012, Shandong, People's Republic of China.

Fucoidan is a complex sulfated polysaccharide with a wide variety of biological activities for modulating immune cell functions. However, the effects of fucoidan on maturation process and activation of human monocyte-derived dendritic cells (DCs) remain to be elucidated. The present study demonstrated that the level of special marks and polarization phenotype of DCs was altered by fucoidan. Human monocytes were cultured with GM-CSF and IL-4 for 5 days followed by another 2 days in the presence of fucoidan or LPS. Then DCs were harvested on day 7 and were examined using functional assays. We demonstrated that fucoidan up-regulated the expression of HLA-DR and co-stimulatory molecules of DCs. However the endocytic activity was impaired markedly. Fucoidan induces their Th1-promoting tumor necrosis factor alpha (TNF-alpha) and interleukin-12 (IL-12) secretion, and enhances their allostimulatory capacity. In an allogeneic MLR assay, DCs treated with fucoidan were potent in the secretion of IL-12p70, TNF-alpha and IFN-gamma. Naive T cells stimulated by fucoidan-treated DCs differentiated towards a helper T cell type 1 (Th1) response depending on IL-12 secretion. These results suggest that fucoidan may induce immature DCs maturation and drive their differentiation towards a Th1-polarizing phenotype. Moreover, our data suggest that DCs appear to be a potential target for the immunomodulatory capacity of fucoidan and fucoidan may be used on DC-based vaccines for cancer immunotherapy.

PMID: 18783737 [PubMed - as supplied by publisher] @


Fucoidan induces apoptosis of human HS-sultan cells accompanied by activation of caspase-3 and down-regulation of ERK pathways. Aisa Y, Miyakawa Y, Nakazato T, Shibata H, Saito K, Ikeda Y, Kizaki M.

Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan.

Fucoidan, a sulfated polysaccharide in brown seaweed, was found to inhibit proliferation and induce apoptosis in human lymphoma HS-Sultan cell lines. Fucoidan-induced apoptosis was accompanied by the activation of caspase-3 and was partially prevented by pretreatment with a pan-caspase inhibitor, z-VAD-FMK. The mitochondrial potential in HS-Sultan cells was decreased 24 hr after treatment with fucoidan, indicating that fucoidan induced apoptosis through a mitochondrial pathway. When HS-Sultan was treated with 100 microg/mL fucoidan for 24 hr, phosphorylation of ERK and GSK markedly decreased. In contrast, phosphorylation of p38 and Akt was not altered by treatment with fucoidan. L-selectin and P-selectin are known to be receptors of fucoidan; however, as HS-Sultan does not express either of these selectins, it is unlikely that fucoidan induced apoptosis through them in HS-Sultan. The neutralizing antibody, Dreg56, against human L-selectin did not prevent the inhibitory effect of fucoidan on the proliferation of IM9 and MOLT4 cells, both of which express L-selectin; thus it is possible fucoidan induced apoptosis though different receptors. These results demonstrate that fucoidan has direct anti-cancer effects on human HS-Sultan cells through caspase and ERK pathways.

PMID: 15609279 [PubMed - indexed for MEDLINE]

CANCER CELLS - Limu and Apoptosis
Cells die in two ways - by necrosis, which is cell death from an injury, like a burn or loss of blood; and by apoptosis, or programmed cell suicide as part of the cell life cycle. Apoptosis has held the attention of cancer researchers for the past several decades. Understanding this preprogramed death means cancer therapies could be targeted to either induce apoptosis or work with it.

In technical terms, in apoptosis, cells undergo a process of chromatin condensations, DNA fragmentation, blebbing (like blistering) of the plasma membrane, and cell shrinkage, according to Shailaja Kasibhatla and Ben Tseng's June 2003 article in Molecular Cancer theraputics. They also explain that in contrast to necrosis, "Apoptosis is associated with the rapid engulfment and removal of cell corpses by phagocytic cells {cells that consume cells and particulates as part of our bodily defense mechanism} that recognize 'eat me' signals displayed on the outer surface of the apoptotic cell. Furthermore, apoptotic cell death is the consequence of a series of precisely regulated events that are frequently altered in tumor cells.

Cancer therapy inducing apoptosis would tune in on cancer cells giving off 'eat me' signals. But a lot of things have to coordinate to ensure programmed cell death. This is important because if cells don't die a natural death, cancer may cause them to grow and divide in an uncontrollable manner. Then the healthy cells going through their normal life cycle cannot produce enough healthy cells to leep the organism alive, our bodies in this instance, because the cancer takes over.

Cancer researchers are unusually fixated on apoptosis and are intrigued by any substance that will spur this process in cancer cells. Fucoidan, the key nutrient in limu is a substance that has caught the attention of many researchers looking for a way to induce apoptosis. The number of studies of fucoidan and its application as a cancer therapy rival the number of those studying fucoidan's use as an anticoagulant substitute.

Yoshitaka Miyakawa, M.D., an assistant professor in the Department of Internal Medicine at Keio University School of Medicine in Tokyo, is interested in exploring fucoidan's use as a cancer therapy. "We were prompted to fucoidan by the fact that fucoidan is the natural compound and might be safe for the patients as an anti-cancer treatment. As you know, fucoidan is a sulfated polysaccharide present in brown seaweed and has anit-cancer effects through the modulation of host immune systems.

"Fucoidan prevents the attachment of Helicobacter pylori to the mucinof the gastric tract, indicating fucoidan has potential to treat gastric ulcer and prevent gastric cancer. In our study {"Fucoidan Induces Apoptosis of Human HS-Sultan Cell accompanied by Activation opf Caspase-3 and Down-Regulation of ERK Pathways, "American Journal of Hematology (2005), we demonstrated that fucoidan from brown seaweed directly induces apoptosis in human lymphoma and myeloma cell lines."

Miyakawa notes that many other studies are cited in the introduction of his work. He and his colleagues acknowledge the work looking at fucoidan anticoagulant and anti-cancer qualities. He says that he sees great potential in fucoidan as a cancer therapy. "As a hematology-oncology doctor, we are interested in developing the new anti-cancer drugs with fewer side effects for patients."

The many studies looking at fucoidan's anti-cancer effects extend to breast and lung cancer and leukemia. Also, fucoidan has shown anti-antiogenesis ability, in which a substance chokes off a tumor's blood supply, and the important ability to induce apoptosis in cancer cells. Fucoidan's role as apotential cancer therapy is sure to hold science's interest for a long time.

Volume 1 Issue 3 Breakthroughs in Health    October 2005


Logo - 468X60banner

Note for legal purposes: Personal testimonials in this article reflect individual experiences and are not necessarily typical of the results everyone might obtain. Earnings for TLC distributors will depend on a number of factors including your individual effort, skill and leadership abilities. No earnings guarantees are expressed or implied. Claims in this article have not been evaluated by the Food and Drug Administration. Original Limu is a food product, not a drug and is not intended to diagnose, cure, prevent or treat any illness or disease.